Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Insights - Quanterix Corporation reported a quarterly loss of $0.36 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.23, marking an earnings surprise of -56.52% [1] - The company generated revenues of $40.23 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 4.18% and showing an increase from $35.81 million year-over-year [2] - Quanterix shares have declined approximately 53.5% year-to-date, contrasting with the S&P 500's gain of 14.4% [3] Financial Performance - Over the last four quarters, Quanterix has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $39.85 million, and for the current fiscal year, it is -$1.25 on revenues of $133.4 million [7] Industry Context - The Medical - Products industry, to which Quanterix belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Quanterix's stock outlook [5][6]

Quanterix (NasdaqGM:QTRX) Q3 2025 Earnings Call November 10, 2025 04:30 PM ET Speaker0Hello and thank you for standing by. My name is Tiffany and I will be your conference operator today. At this time I would like to welcome everyone to the Quanterix Corporation Q3 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during that time, simply press Star then the num ...

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Financial Position - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities of $134.8 million, with an accumulated deficit of $554.1 million[182]. - The company expects to incur operating losses into 2026 due to increased research and development expenses and costs related to acquisitions[183]. - The company expects negative cash flows from operating activities to continue at least through 2025 due to ongoing investments in technology and infrastructure[246]. Revenue Performance - Total revenues increased by $4.4 million, or 12%, to $40.2 million for the three months ended September 30, 2025, compared to $35.8 million for the same period in 2024[199]. - Total revenues decreased by $7.2 million, or 7%, to $95.0 million for the nine months ended September 30, 2025, compared to $102.3 million for the same period in 2024[220]. - Product revenue rose by $6.5 million, or 33%, to $26.2 million, primarily due to the acquisition of Akoya, which contributed $11.3 million, while the legacy Quanterix business decreased by $4.8 million, or 25%[200]. Operating Expenses - Operating expenses surged by $22.6 million, or 71%, to $54.5 million, with significant increases in selling, general, and administrative expenses due to the Akoya acquisition[212]. - The company implemented actions to reduce annualized operating expenses by approximately $67.0 million, with a target of $85.0 million in reductions[192]. - Selling, general and administrative expenses surged by $29.8 million, or 41%, to $102.9 million, influenced by non-recurring costs related to acquisitions[230][231]. Acquisitions and Synergies - The acquisition of Akoya Biosciences in July 2025 is expected to generate synergies that will offset anticipated operating losses, with a goal of achieving cash flow breakeven in 2026[184]. - The company completed the acquisition of Emission, Inc. in January 2025, with an upfront payment of $9.0 million and potential earnout payments of up to $50.0 million[188]. - The acquisition of Emission includes potential additional cash payments of up to $60 million based on performance targets and technical milestones[253]. Impairment and Restructuring - The company recorded a goodwill impairment charge of $6.4 million in the second quarter of 2025 due to a decline in revenue and bookings[191]. - The company recorded impairment and restructuring costs of $7.2 million related to severance and the impairment of a leased facility from the Akoya acquisition[215]. - Impairment and restructuring costs amounted to $14.8 million, reflecting a goodwill impairment charge and severance expenses from the 2025 restructuring[234]. Cash Flow and Investments - Net cash used in operating activities was $60.8 million for the nine months ended September 30, 2025, compared to $30.9 million for the same period in 2024, reflecting a $29.9 million increase in cash used[247]. - Net cash provided by investing activities was $41.8 million during the nine months ended September 30, 2025, primarily from $183.4 million in proceeds from sales and maturities of marketable securities[249]. - Cash used in operations included payments for professional fees related to the acquisition of Akoya[247]. Certification and Compliance - The company received ISO 13485 certification for its operations in Billerica, Massachusetts, indicating compliance with international standards for medical device manufacturing[197]. Market Conditions - The company expects continued softness in instrument sales due to a constrained capital funding environment, with a recovery anticipated as funding conditions improve[201]. - There have been no material changes to market risk information as of September 30, 2025, compared to previous disclosures[280].

Third Quarter 2025 Earnings November 10, 2025 " Legal Information CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements included in this press release that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include ...

Financial Performance - Revenue for Q3 2025 was $40.2 million, a 12.3% increase from $35.8 million in Q3 2024[7] - The net loss for Q3 2025 was $33.5 million, compared to a net loss of $8.4 million in Q3 2024[12] - For the three months ended September 30, 2025, the net loss was $33.517 million, compared to a net loss of $8.353 million for the same period in 2024[22] - Total revenues for the three months ended September 30, 2025, were $40.233 million, an increase from $35.813 million in the same period of 2024[22] - The company reported total operating expenses of $54.531 million for the three months ended September 30, 2025, compared to $31.901 million in 2024[28] Margins and Profitability - GAAP gross margin decreased to 42.8% from 56.3% in the prior year, while adjusted gross margin was 45.9%, down from 50.7%[7] - Adjusted EBITDA loss was $11.9 million, compared to a loss of $5.5 million in the prior year, primarily due to higher acquisition and restructuring charges[7] - Adjusted EBITDA for the three months ended September 30, 2025, was $(11.885) million, with an adjusted EBITDA margin of (29.5)%, compared to $(5.470) million and (15.3)% in 2024[22] - Adjusted gross profit for the three months ended September 30, 2025, was $18.468 million, with an adjusted gross margin of 45.9%, compared to $18.142 million and 50.7% in 2024[28] Cash Flow and Guidance - The company ended Q3 2025 with $138.1 million in cash and equivalents, with adjusted cash usage of $16.1 million expected to decline in Q4 2025[7] - Quanterix expects adjusted cash usage for 2025 to be approximately $34 to $38 million, aiming for cash flow breakeven in 2026[8] - Adjusted cash usage for the three months ended September 30, 2025, was $(16.063) million, compared to $(3.330) million in the same period of 2024[25] Strategic Initiatives - Quanterix is reiterating its 2025 revenue guidance of $130 to $135 million, with pro forma revenue expected to be between $165 and $170 million assuming full-year performance from Akoya[6] - The company achieved $67 million in cost synergies from the Akoya integration, consolidating sales organizations and manufacturing facilities[7] - Quanterix launched eight new Simoa assays in the first nine months of 2025 and established new partnerships in the Asia-Pacific region[7] - The company anticipates potential benefits from the acquisition of Akoya Biosciences Inc. and the launch of its next-generation instrument, Simoa One[31] Risks and Challenges - The company is facing risks related to the integration of its business with Akoya and the realization of expected benefits from recent acquisitions[31] - The company reported a significant increase in impairment and restructuring costs, totaling $7.174 million for the three months ended September 30, 2025[28] - The company incurred acquisition and integration related costs of $7.315 million for the three months ended September 30, 2025[21]

Core Viewpoint - Quanterix Corporation (QTRX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook driven by an upward trend in earnings estimates [1][2] Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of changing earnings estimates, which are strongly correlated with near-term stock price movements [3][5] - Institutional investors utilize earnings estimates to determine the fair value of stocks, influencing their buying and selling actions, which subsequently affects stock prices [3] Business Improvement Indicators - The increase in earnings estimates and the Zacks rating upgrade suggest an improvement in Quanterix's underlying business, which could lead to higher stock prices as investors respond positively [4][9] Earnings Estimate Revisions - Quanterix is projected to earn -$1.25 per share for the fiscal year ending December 2025, with no year-over-year change expected [7] - Over the past three months, the Zacks Consensus Estimate for Quanterix has increased by 23.3%, indicating a positive revision trend [7] Zacks Rating System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [6][8] - Quanterix's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [9]

Quanterix (QTRX) FY Conference Summary Company Overview - Quanterix operates in the life sciences tools and diagnostics industry, focusing on ultra-sensitive protein measurement platforms based on digital ELISA [2][4] Key Points and Arguments Financial Guidance and Performance - The company anticipates a significant decline in its core Calynterex business for 2025 [2] - Despite macroeconomic pressures, the consumables business generated approximately $100 million, showing resilience compared to the previous year [4] - Diagnostics revenues tripled, indicating growth potential despite being a small segment [5] - Academic revenues were expected to decline by 20% to 30%, with an actual decline of 18% [6] - The Accelerator business saw a year-over-year revenue drop of 60%, with $4 million in revenue for the quarter [9][10] Business Segments - The Accelerator business had strong performance in previous years but is currently facing pressure due to smaller project sizes and budget constraints [11][12] - The Akoya business is projected to generate $30 million in the second half of the year, down from $82 million last year, primarily due to CDx business milestones [15] Strategic Initiatives - Quanterix aims to create a unified company structure post-Akoya acquisition, focusing on assay development and expanding consumables [19][24] - The company is targeting $85 million in annualized synergies by the end of next year, with 75% already implemented [23] - R&D investment is projected to be 30% of total revenues, emphasizing the importance of innovation [24] Product Development and Market Trends - The upcoming launch of the SMO-one platform aims to enhance sensitivity and multiplexing capabilities for liquid biopsy testing in neurology and oncology [28][29] - The Lucent AD Complete test is positioned as a significant advancement in Alzheimer's diagnostics, with plans for FDA submission and reimbursement efforts [34][36] - The company is actively working on integrating new biomarkers into its tests, enhancing diagnostic capabilities [39] Market Position and Future Outlook - Quanterix is optimistic about the translational market, particularly in understanding spatially resolved biomarkers in tissue [21] - The company believes that the integration of Akoya will enhance its oncology capabilities and expand its customer base [44] - The goal for 2026 includes achieving cash flow breakeven and maintaining a strong balance sheet with over $100 million [52] Additional Important Insights - The company is focused on increasing throughput and efficiency in its operations, leveraging existing technologies without requiring new instruments [50] - Quanterix is committed to developing a diverse range of assays to meet market demands and drive revenue growth [47] - The management expresses confidence in achieving its strategic goals and delivering value to shareholders despite current market challenges [52][53]

Core Viewpoint - Quanterix Corporation (QTRX) has experienced a significant decline of 24.3% in its stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround as analysts expect better earnings than previously predicted [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to determine if a stock is oversold, with a reading below 30 typically indicating this condition [2]. - QTRX's current RSI reading is 28.07, indicating that the heavy selling pressure may be exhausting itself, which could lead to a reversal in the stock's trend [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts regarding an increase in earnings estimates for QTRX, with the consensus EPS estimate rising by 23.3% over the last 30 days [7]. - An upward trend in earnings estimate revisions is generally associated with price appreciation in the near term, supporting the case for a potential turnaround [7]. Group 3: Analyst Ratings - QTRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8].